LP14 : A phase 3, randomised, open-label study to evaluate...

LP14 : A phase 3, randomised, open-label study to evaluate the efficacy and safety of 8 and 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve and -experienced patients with chronic HCV genotype 1 infection without cirrhosis: Optimist-1

Kwo, P., Gitlin, N., Nahass, R., Bernstein, D., Rojter, S., Schiff, E., Davis, M., Ruane, P.J., Younes, Z., Kalmeijer, R., Peeters, M., Lenz, O., Fevery, B., De La Rosa, G., Scott, J., Sinha, R., Wite
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
62
Language:
english
Journal:
Journal of Hepatology
DOI:
10.1016/S0168-8278(15)30168-9
Date:
April, 2015
File:
PDF, 118 KB
english, 2015
Conversion to is in progress
Conversion to is failed